[An overview of therapeutic agents for dysuria].
Masuda
Noriyuki
N
noriyuki.masuda@jp.astellas.com
Suzuki
Masanori
M
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000368:Aged; D000818:Animals; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004195:Disease Models, Animal; D053159:Dysuria / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications; D011966:Receptors, LHRH / Q000037:antagonists & inhibitors; D014550:Urinary Incontinence, Stress / Q000188:drug therapy
D011966:Receptors, LHRH; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human